Home › Filings & Releases › March 2026

Filings & Releases — March 2026

670 documents from 243 companies (2 releases) · updated Nov 7, 2026

Company

All filings (+293)

Tuesday, March 3138

Monday, March 3035

ZBIOZenas BioPharma424B5Prospectus supplement (offering)
ZBIOZenas BioPharma424B5Prospectus supplement (offering)
XNCRXencorSCHEDULE 13GPassive >5% holder (13G)
WVEWave Life SciencesSCHEDULE 13D/A13D amendment
VRDNViridian Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
VORVor BiopharmaS-8Employee plan registration
VORVor Biopharma10-KAnnual report
UNCYUnicycive Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED MARCH 30, 2026
UNCYUnicycive Therapeutics10-KAnnual report
TARAProtara Therapeutics8-KCurrent report: Reg FD disclosure
STROSutro BiopharmaCORRESPCORRESP
RVPHReviva PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
RVPHReviva PharmaceuticalsS-8Employee plan registration
RVPHReviva Pharmaceuticals8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
RVPHReviva Pharmaceuticals10-KAnnual report
RNACCartesian Therapeutics8-KCurrent report: officer / director change
RAREUltragenyx Pharmaceutical8-KCurrent report: other events
PHIOPhio Pharmaceuticals8-KCurrent report: other events · EX-99 EXHIBIT 99
PEPGPepGen8-KCurrent report: Reg FD disclosure, other events · EX-99.1
ONCYOncolytics Biotech10-KAnnual report
OKUROnKure Therapeutics8-KCurrent report: material agreement, unregistered sale of equity, officer / director change
MGTXMeiraGTx10-KAnnual report
LXEOLexeo TherapeuticsS-8Employee plan registration
LXEOLexeo Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
LXEOLexeo Therapeutics10-KAnnual report
KZIAKazia TherapeuticsSCHEDULE 13G/A13G amendment
KZIAKazia Therapeutics6-KForeign issuer report · EX-99.1 HALF-YEAR REPORT FOR THE SIX MONTHS ENDED DECEMBER 31, 2025
KYTXKyverna TherapeuticsUPLOADUPLOAD
KTTAPasithea Therapeutics10-KAnnual report
INMBInmune Bio10-KAnnual report
IMMXImmix Biopharma8-KCurrent report: Reg FD disclosure, other events · EX-99.1
FDMT4D Molecular Therapeutics8-KCurrent report: officer / director change
FBIOFortress Biotech8-KCurrent report: other events · EX-99
EIKNEikon Therapeutics8-KCurrent report: results of operations · EX-99.1
EIKNEikon Therapeutics10-KAnnual report
CNTBConnect Biopharma8-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1
BCAXBicara Therapeutics8-KCurrent report: results of operations · EX-99.1
BCAXBicara Therapeutics10-KAnnual report
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ANNXAnnexon8-KCurrent report: results of operations · EX-99.1
ANNXAnnexon10-KAnnual report
AKTSAktis Oncology8-KCurrent report: results of operations · EX-99.1
AKTSAktis Oncology10-KAnnual report
ABOSAcumen PharmaceuticalsUPLOADUPLOAD
ABOSAcumen PharmaceuticalsCORRESPCORRESP
AARDAardvark TherapeuticsCORRESPCORRESP

Friday, March 2730

Thursday, March 2642

Wednesday, March 2523

RXRXRecursion Pharmaceuticals8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
RVPHReviva PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
RCKTRocket PharmaceuticalsPRE 14APRE 14A
PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
PMNProMIS NeurosciencesS-3Shelf registration
PMNProMIS Neurosciences8-KCurrent report: results of operations · EX-99.1
PMNProMIS Neurosciences10-KAnnual report
OTLKOutlook Therapeutics8-KCurrent report: other events
OTLKOutlook Therapeutics424B5Prospectus supplement (offering)
NKTXNkartaS-3Shelf registration
NKTXNkarta8-KCurrent report: results of operations · EX-99.1
NKTXNkarta10-KAnnual report
MAZEMaze Therapeutics8-KCurrent report: results of operations, officer / director change, Reg FD disclosure · EX-99.1
MAZEMaze Therapeutics10-KAnnual report
LGVNLongeveronDForm D (exempt offering)
LGVNLongeveron8-KCurrent report: listing notice
KZIAKazia TherapeuticsUPLOADUPLOAD
KPRXKiora PharmaceuticalsS-8Employee plan registration
KPRXKiora Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
KPRXKiora Pharmaceuticals10-KAnnual report
IXHLIncannex Healthcare8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF MARCH 25, 2026
IMMXImmix BiopharmaS-8Employee plan registration
IMMXImmix Biopharma8-KCurrent report: material agreement
IMMXImmix Biopharma424B5Prospectus supplement (offering)
IMMXImmix Biopharma10-KAnnual report
GHRSGH Research6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
CYDYCytoDyn424B3Prospectus (resale / update)
APGEApogee Therapeutics8-KCurrent report: material agreement
APGEApogee Therapeutics424B5Prospectus supplement (offering)
ANTXAN2 TherapeuticsDForm D (exempt offering)
AARDAardvark TherapeuticsUPLOADUPLOAD

Tuesday, March 2431

Monday, March 2326

STROSutro BiopharmaS-8Employee plan registration
STROSutro BiopharmaS-3Shelf registration
STROSutro Biopharma8-KCurrent report: agreement terminated, results of operations · EX-99.1
STROSutro Biopharma10-KAnnual report
SABSSAB BiotherapeuticsSCHEDULE 13D/A13D amendment
RCUSArcus Biosciences8-KCurrent report: officer / director change
PMNProMIS NeurosciencesUPLOADUPLOAD
OTLKOutlook Therapeutics424B5Prospectus supplement (offering)
NRXPNRX Pharmaceuticals10-KAnnual report
MESOMesoblast6-KForeign issuer report · EX-99.1
MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
MAIAMAIA Biotechnology10-KAnnual report
LCTXLineage Cell TherapeuticsEFFECTRegistration effective
IRDOpus GeneticsDEF 14AProxy statement
IRDOpus GeneticsARSAnnual report to shareholders
INSMInsmed8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
HELPHelus PharmaDForm D (exempt offering)
CUECue BiopharmaUPLOADUPLOAD
CRVOCervoMed8-KCurrent report: Reg FD disclosure
CRNXCrinetics Pharmaceuticals8-KCurrent report: officer / director change
CMMBChemomab Therapeutics20-FAnnual report (foreign)
CINGCingulateS-3/AShelf registration (amended)
CINGCingulateCORRESPCORRESP
CABACabaletta BioS-8Employee plan registration
CABACabaletta Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
CABACabaletta Bio10-KAnnual report
APGEApogee Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
APGEApogee Therapeutics424B5Prospectus supplement (offering)
ACRVAcrivon TherapeuticsSCHEDULE 13D/A13D amendment
ACETAdicet BioEFFECTRegistration effective
ABVXAbivaxS-8Employee plan registration
ABVXAbivax6-KForeign issuer report · EX-99.1
ABVXAbivax20-FAnnual report (foreign)
AARDAardvark TherapeuticsS-3Shelf registration
AARDAardvark Therapeutics8-KCurrent report: results of operations · EX-99.1
AARDAardvark Therapeutics10-KAnnual report

Friday, March 2021

XFORX4 PharmaceuticalsDEFA14AProxy soliciting material
XFORX4 PharmaceuticalsDEF 14AProxy statement
XFORX4 PharmaceuticalsARSAnnual report to shareholders
TLXTelix Pharmaceuticals20-F/AAnnual report (foreign, amended)
TGTXTg Therapeutics8-KCurrent report: material agreement, debt / obligation
SPRBSpruce Biosciences8-KCurrent report: agreement terminated · EX-99.1
SLSSELLAS Life Sciences GroupS-3ASRAutomatic shelf registration
RYTMRhythm Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1
RLMDRelmada Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 PRESS RELEASE DATED MARCH 19, 2026, REGARDING CORPORATE UPDATE AND FULL YEAR 202
PALIPalisade Bio10-KAnnual report
ONCYOncolytics Biotech8-KCurrent report: holder rights modified, charter / bylaws / fiscal year
OLMAOlema PharmaceuticalsSCHEDULE 13GPassive >5% holder (13G)
OCGNOcugen8-KCurrent report: other events
MRKRMarker TherapeuticsDEFA14AProxy soliciting material
MRKRMarker TherapeuticsDEF 14AProxy statement
MRKRMarker TherapeuticsARSAnnual report to shareholders
MISTMilestone Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
MISTMilestone Pharmaceuticals10-KAnnual report
IMMXImmix BiopharmaSCHEDULE 13GPassive >5% holder (13G)
FBIOFortress BiotechSCHEDULE 13D/A13D amendment
EYPTEyePoint8-KCurrent report: Reg FD disclosure
ELOXEloxx PharmaceuticalsDRSDRS
COYACoya TherapeuticsEFFECTRegistration effective
COYACoya Therapeutics424B3Prospectus (resale / update)
CMMBChemomab Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
CINGCingulateS-3Shelf registration
ANTXAN2 Therapeutics8-KCurrent report: officer / director change

Thursday, March 1942

ZURAZura Bio8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
ZURAZura Bio10-KAnnual report
TSHATaysha Gene Therapies8-KCurrent report: results of operations · EX-99.1
TSHATaysha Gene Therapies10-KAnnual report
SLSSELLAS Life Sciences Group8-KCurrent report: results of operations · EX-99.1
SLSSELLAS Life Sciences Group10-KAnnual report
SLDBSolid BiosciencesS-8Employee plan registration
SLDBSolid BiosciencesS-3Shelf registration
SLDBSolid BiosciencesS-3Shelf registration
SLDBSolid Biosciences10-KAnnual report
SABSSAB Biotherapeutics8-KCurrent report: material agreement, other events · EX-99.1
SABSSAB Biotherapeutics424B5Prospectus supplement (offering)
RVPHReviva Pharmaceuticals8-KCurrent report: material agreement, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
RVPHReviva Pharmaceuticals424B5Prospectus supplement (offering)
RLMDRelmada Therapeutics10-KAnnual report
RLAYRelay TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
MRKRMarker Therapeutics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
MBRXMoleculin Biotech8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
MBRXMoleculin Biotech8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
LRMRLarimar TherapeuticsS-8Employee plan registration
LRMRLarimar Therapeutics8-KCurrent report: results of operations · EX-99.1
LRMRLarimar Therapeutics10-KAnnual report
LCTXLineage Cell TherapeuticsCORRESPCORRESP
KZIAKazia Therapeutics6-KForeign issuer report · EX-99.1
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KZIAKazia Therapeutics424B3Prospectus (resale / update)
KZIAKazia Therapeutics424B3Prospectus (resale / update)
INKTMiNK Therapeutics8-KCurrent report: officer / director change
INBXInhibrx Biosciences8-KCurrent report: results of operations · EX-99.1
INBXInhibrx Biosciences10-KAnnual report
GNLXGeneluxS-8Employee plan registration
GNLXGenelux8-KCurrent report: material agreement
GNLXGenelux424B5Prospectus supplement (offering)
GNLXGenelux10-KAnnual report
GLUEMonte Rosa TherapeuticsSCHEDULE 13D/A13D amendment
ETONEton Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
ETONEton Pharmaceuticals10-KAnnual report
ELDNEledon Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
ELDNEledon Pharmaceuticals10-KAnnual report
CTMXCytomX Therapeutics8-KCurrent report: other events
CRVOCervoMed8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
COYACoya TherapeuticsUPLOADUPLOAD
COYACoya TherapeuticsCORRESPCORRESP
CMMBChemomab Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 PROPOSED ISSUE OF SECURITIES - ATH
ACRVAcrivon TherapeuticsS-8Employee plan registration
ACRVAcrivon Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
ACRVAcrivon Therapeutics10-KAnnual report
ACETAdicet BioCORRESPCORRESP

Wednesday, March 1820

XFORX4 PharmaceuticalsS-8Employee plan registration
STOKStoke TherapeuticsS-3ASRAutomatic shelf registration
RVPHReviva Pharmaceuticals424B5Prospectus supplement (offering)
PMNProMIS NeurosciencesSCHEDULE 13GPassive >5% holder (13G)
PMNProMIS NeurosciencesS-3Shelf registration
PCSAProcessa Pharmaceuticals10-KAnnual report
OVIDOvid TherapeuticsS-8Employee plan registration
OVIDOvid Therapeutics8-KCurrent report: material agreement, results of operations, unregistered sale of equity · EX-99.1
OVIDOvid Therapeutics10-KAnnual report
MRKRMarker Therapeutics10-KAnnual report
MESOMesoblast6-KForeign issuer report · EX-99.1
MBRXMoleculin Biotech10-KAnnual report
KZIAKazia TherapeuticsF-3Shelf registration (foreign)
IXHLIncannex Healthcare8-KCurrent report: Reg FD disclosure · EX-99.1 PRESS RELEASE DATED AS OF MARCH 18, 2026
GOSSGossamer BioEFFECTRegistration effective
GANXGain Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
FDMT4D Molecular TherapeuticsS-8Employee plan registration
FDMT4D Molecular Therapeutics8-KCurrent report: results of operations · EX-99.1
FDMT4D Molecular Therapeutics10-KAnnual report
CTMXCytomX Therapeutics424B5Prospectus supplement (offering)
CINGCingulateDEFA14AProxy soliciting material
CINGCingulate8-KCurrent report: results of operations, other events · EX-99.1
CINGCingulate10-KAnnual report
CADLCandel TherapeuticsSCHEDULE 13D/A13D amendment
ARVNArvinas8-KCurrent report: Reg FD disclosure, other events · EX-99.1
ADAGAdageneSCHEDULE 13GPassive >5% holder (13G)
ACETAdicet BioUPLOADUPLOAD

Tuesday, March 1724

XFORX4 Pharmaceuticals10-KAnnual report
SLDBSolid BiosciencesSCHEDULE 13D/A13D amendment
SABSSAB Biotherapeutics424B5Prospectus supplement (offering)
LGVNLongeveron10-KAnnual report
IXHLIncannex Healthcare8-KCurrent report: listing notice, other events · EX-99.1 PRESS RELEASE ISSUED BY INCANNEX HEALTHCARE INC., DATED MARCH 17, 2026
IRDOpus GeneticsUPLOADUPLOAD
GUTSFractyl Health8-KCurrent report: listing notice
GOSSGossamer BioPOSASRPOSASR
GOSSGossamer BioPOS AMPost-effective amendment
GOSSGossamer Bio8-KCurrent report: results of operations · EX-99.1
GOSSGossamer Bio10-KAnnual report
GLUEMonte Rosa TherapeuticsS-8Employee plan registration
GLUEMonte Rosa Therapeutics8-KCurrent report: results of operations · EX-99.1
GLUEMonte Rosa Therapeutics10-KAnnual report
ELOXEloxx Pharmaceuticals10-KAnnual report
DTILPrecision Biosciences8-KCurrent report: Reg FD disclosure · EX-99.1
CRVOCervoMed8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
CLNNClene8-KCurrent report: material agreement
CLNNClene10-KAnnual report
CBIOCrescent Biopharma424B3Prospectus (resale / update)
CAPRCapricor Therapeutics10-KAnnual report
BCYCBicycle TherapeuticsS-8Employee plan registration
BCYCBicycle Therapeutics8-KCurrent report: results of operations, officer / director change · EX-99.1 EXHIBIT 99.1
BCYCBicycle Therapeutics10-KAnnual report
ANTXAN2 TherapeuticsS-8Employee plan registration
ANTXAN2 Therapeutics8-KCurrent report: results of operations · EX-99.1
ANTXAN2 Therapeutics10-KAnnual report
ALTAltimmuneDEF 14AProxy statement
ALTAltimmuneARSAnnual report to shareholders
ALDXAldeyra Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
ACRSAclaris TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
ABOSAcumen PharmaceuticalsSCHEDULE 13D/A13D amendment

Monday, March 1637

ZBIOZenas BioPharmaS-8Employee plan registration
ZBIOZenas BioPharmaDEFA14AProxy soliciting material
ZBIOZenas BioPharmaDEF 14AProxy statement
ZBIOZenas BioPharmaARSAnnual report to shareholders
ZBIOZenas BioPharma8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
ZBIOZenas BioPharma10-KAnnual report
VORVor BiopharmaSCHEDULE 13D/A13D amendment
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
STOKStoke TherapeuticsS-8Employee plan registration
STOKStoke Therapeutics10-KAnnual report
RYTMRhythm Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1
RLAYRelay Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
OTLKOutlook Therapeutics8-KCurrent report: material agreement, debt / obligation, other events · EX-99.1 EXHIBIT 99.1
OLMAOlema PharmaceuticalsS-8Employee plan registration
OLMAOlema Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
OLMAOlema Pharmaceuticals10-KAnnual report
NRSNNeuroSense Therapeutics6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED MARCH 16, 2026
NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1
LCTXLineage Cell TherapeuticsUPLOADUPLOAD
LBRXLB Pharmaceuticals8-KCurrent report: officer / director change
GPCRStructure Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
GHRSGH Research6-KForeign issuer report
ELTXElicio TherapeuticsEFFECTRegistration effective
ELTXElicio Therapeutics8-KCurrent report: material agreement, agreement terminated
ELTXElicio Therapeutics424B5Prospectus supplement (offering)
CUECue BiopharmaS-3Shelf registration
CUECue BiopharmaDEF 14AProxy statement
CUECue BiopharmaARSAnnual report to shareholders
CUECue Biopharma8-KCurrent report: results of operations · EX-99.1
CUECue Biopharma10-KAnnual report
CTMXCytomX TherapeuticsS-3ASRAutomatic shelf registration
CTMXCytomX Therapeutics8-KCurrent report: results of operations · EX-99.1
CTMXCytomX Therapeutics424B5Prospectus supplement (offering)
CTMXCytomX Therapeutics10-KAnnual report
COYACoya TherapeuticsS-3Shelf registration
COYACoya Therapeutics8-KCurrent report: results of operations · EX-99.1
COYACoya Therapeutics10-KAnnual report
CATXPerspective Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
CATXPerspective Therapeutics10-KAnnual report
BDTXBlack Diamond TherapeuticsS-8Employee plan registration
BDTXBlack Diamond Therapeutics8-KCurrent report: results of operations · EX-99.1
BDTXBlack Diamond Therapeutics10-KAnnual report
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 ATH - UNMARKETABLE PARCEL SALE FACILITY
ANTXAN2 TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
ADCTADC TherapeuticsEFFECTRegistration effective
ADCTADC Therapeutics424B3Prospectus (resale / update)
ABOSAcumen Pharmaceuticals8-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1

Friday, March 1311

XENEXenon Pharmaceuticals8-KCurrent report: other events · EX-99.1
RNACCartesian TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
NKTRNektar Therapeutics10-KAnnual report
NGENNervGen Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
MESOMesoblast6-KForeign issuer report · EX-99.1
IRDOpus GeneticsS-3Shelf registration
CRVSCorvus PharmaceuticalsS-3ASRAutomatic shelf registration
CRVSCorvus Pharmaceuticals8-KCurrent report: material agreement
CRVSCorvus Pharmaceuticals424B5Prospectus supplement (offering)
CRVOCervoMed10-KAnnual report
ANTXAN2 TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
ANTXAN2 TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
ACIUAC Immune6-KForeign issuer report · EX-99.1
ACIUAC Immune20-FAnnual report (foreign)

Thursday, March 1245

XENEXenon Pharmaceuticals8-KCurrent report: material agreement, other events
XENEXenon Pharmaceuticals424B5Prospectus supplement (offering)
SLDBSolid Biosciences8-KCurrent report: Reg FD disclosure, other events
RAREUltragenyx Pharmaceutical8-KCurrent report: other events
QTTBQ32 BioSCHEDULE 13D/A13D amendment
PRQRProQR Therapeutics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
PRQRProQR Therapeutics20-FAnnual report (foreign)
PRLDPrelude Therapeutics8-KCurrent report: other events
PRLDPrelude Therapeutics424B5Prospectus supplement (offering)
ORKAOruka TherapeuticsS-8Employee plan registration
ORKAOruka Therapeutics10-KAnnual report
OKUROnKure TherapeuticsS-8Employee plan registration
OKUROnKure Therapeutics8-KCurrent report: results of operations · EX-99.1
OKUROnKure Therapeutics10-KAnnual report
NKTRNektar Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2
MLYSMineralys Therapeutics8-KCurrent report: results of operations · EX-99.1
MLYSMineralys Therapeutics10-KAnnual report
MESOMesoblast6-KForeign issuer report · EX-99.1
LGVNLongeveron8-KCurrent report: material agreement, unregistered sale of equity, charter / bylaws / fiscal year · EX-99.1 PRESS RELEASE ISSUED BY THE COMPANY ON MARCH 10, 2026
IXHLIncannex Healthcare8-KCurrent report: material agreement, other events · EX-99.1 PRICING PRESS RELEASE, DATED MARCH 12, 2026
IXHLIncannex Healthcare8-KCurrent report: agreement terminated, Reg FD disclosure, other events · EX-99.1 CORPORATE PRESENTATION, DATED MARCH 12, 2026
IXHLIncannex Healthcare424B5Prospectus supplement (offering)
IRDOpus GeneticsPRE 14APRE 14A
IRDOpus Genetics10-KAnnual report
IPSCCentury TherapeuticsS-8Employee plan registration
IPSCCentury Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
IPSCCentury Therapeutics10-KAnnual report
INABIN8bio8-KCurrent report: results of operations · EX-99.1
INABIN8bio10-KAnnual report
HELPHelus Pharma6-KForeign issuer report · EX-99.1
ERASErasca8-KCurrent report: results of operations · EX-99.1
ERASErasca10-KAnnual report
ENTAEnanta Pharmaceuticals8-KCurrent report: officer / director change, shareholder vote
ELTXElicio TherapeuticsS-8Employee plan registration
ELTXElicio TherapeuticsS-3/AShelf registration (amended)
ELTXElicio TherapeuticsCORRESPCORRESP
ELTXElicio Therapeutics8-KCurrent report: results of operations · EX-99.1
ELTXElicio Therapeutics10-KAnnual report
DTILPrecision Biosciences8-KCurrent report: results of operations · EX-99.1
DTILPrecision Biosciences10-KAnnual report
CRVSCorvus Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE
CRVSCorvus Pharmaceuticals10-KAnnual report
COYACoya TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
CMPXCompass TherapeuticsS-8Employee plan registration
CLNNClene8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
CAPRCapricor Therapeutics8-KCurrent report: results of operations · EX-99.1
CADLCandel TherapeuticsS-8Employee plan registration
CADLCandel Therapeutics8-KCurrent report: results of operations · EX-99.1
CADLCandel Therapeutics10-KAnnual report
ALLOAllogene TherapeuticsS-8Employee plan registration
ALLOAllogene Therapeutics8-KCurrent report: results of operations · EX-99.1
ALLOAllogene Therapeutics10-KAnnual report
ADCTADC TherapeuticsUPLOADUPLOAD
ADCTADC TherapeuticsCORRESPCORRESP
ACETAdicet BioS-8Employee plan registration
ACETAdicet BioS-3Shelf registration
ACETAdicet Bio8-KCurrent report: results of operations · EX-99.1
ACETAdicet Bio10-KAnnual report

Wednesday, March 1120

XENEXenon PharmaceuticalsFWPFree writing prospectus (offering terms)
VRCAVerrica Pharmaceuticals8-KCurrent report: results of operations · EX-99.1
VRCAVerrica Pharmaceuticals10-KAnnual report
VERAVera TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
SLSSELLAS Life Sciences Group8-KCurrent report: other events
SLDBSolid BiosciencesSCHEDULE 13D/A13D amendment
SGMTSagimet BiosciencesS-8Employee plan registration
SGMTSagimet BiosciencesS-8Employee plan registration
SGMTSagimet Biosciences8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
SGMTSagimet Biosciences10-KAnnual report
SABSSAB BiotherapeuticsSCHEDULE 13D/A13D amendment
RLAYRelay Therapeutics8-KCurrent report: charter / bylaws / fiscal year
QNRXQuoin Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
PEPGPepGenSCHEDULE 13GPassive >5% holder (13G)
OTLKOutlook Therapeutics8-KCurrent report: officer / director change · EX-99.1 EXHIBIT 99.1
NRSNNeuroSense Therapeutics6-KForeign issuer report
MESOMesoblastSCHEDULE 13G/A13G amendment
LCTXLineage Cell TherapeuticsS-3Shelf registration
LCTXLineage Cell Therapeutics8-KCurrent report: other events
LCTXLineage Cell Therapeutics424B5Prospectus supplement (offering)
HROWHarrowSCHEDULE 13GPassive >5% holder (13G)
FHTXFoghorn Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
FHTXFoghorn Therapeutics10-KAnnual report
APVOAptevo Therapeutics8-KCurrent report: other events · EX-99.1
ANIXAnixa Biosciences8-KCurrent report: shareholder vote, Reg FD disclosure · EX-99.1
AGMBAgomab TherapeuticsS-8Employee plan registration
ACRSAclaris Therapeutics8-KCurrent report: Reg FD disclosure

Tuesday, March 1041

ZURAZura Bio8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
VTVTvTv Therapeutics8-KCurrent report: Reg FD disclosure · EX-99.1
VTVTvTv Therapeutics8-KCurrent report: results of operations · EX-99.1
VTVTvTv Therapeutics10-KAnnual report
VNDAVanda Pharmaceuticals8-KCurrent report: Reg FD disclosure
TLXTelix Pharmaceuticals6-KForeign issuer report · EX-99.1
TENXTenax TherapeuticsSCHEDULE 13DActivist / >5% holder (13D)
TENXTenax Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE
TENXTenax Therapeutics10-KAnnual report
TARAProtara Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE DATED MARCH 10, 2026, ISSUED BY THE REGISTRANT
TARAProtara Therapeutics10-KAnnual report
SLDBSolid BiosciencesSCHEDULE 13D/A13D amendment
SLDBSolid BiosciencesSCHEDULE 13D/A13D amendment
SEPNSepternaS-3ASRAutomatic shelf registration
SABSSAB Biotherapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
RCKTRocket PharmaceuticalsEFFECTRegistration effective
RCKTRocket Pharmaceuticals8-KCurrent report: material agreement, agreement terminated
RCKTRocket Pharmaceuticals424B5Prospectus supplement (offering)
RAPPRapport TherapeuticsS-8Employee plan registration
RAPPRapport TherapeuticsS-3ASRAutomatic shelf registration
RAPPRapport Therapeutics8-KCurrent report: results of operations · EX-99.1
RAPPRapport Therapeutics10-KAnnual report
QTTBQ32 BioS-8Employee plan registration
QTTBQ32 Bio8-KCurrent report: results of operations · EX-99.1
QTTBQ32 Bio10-KAnnual report
PRLDPrelude TherapeuticsS-8Employee plan registration
PRLDPrelude Therapeutics8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
PRLDPrelude Therapeutics10-KAnnual report
OTLKOutlook Therapeutics8-KCurrent report: shareholder vote
MRKRMarker TherapeuticsPRE 14APRE 14A
LEGNLegend Biotech6-KForeign issuer report · EX-99.1 PRESS RELEASE
LEGNLegend Biotech20-FAnnual report (foreign)
LBRXLB Pharmaceuticals8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1
IRDOpus Genetics8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
HROWHarrow8-KCurrent report: Reg FD disclosure · EX-99.1
CLDXCelldex TherapeuticsSCHEDULE 13G/A13G amendment
CGEMCullinan TherapeuticsS-8Employee plan registration
CGEMCullinan Therapeutics8-KCurrent report: results of operations · EX-99.1
CGEMCullinan Therapeutics10-KAnnual report
CATXPerspective TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
CAPRCapricor Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
BCTXBriaCell Therapeutics10-QQuarterly report
ARTVArtiva BiotherapeuticsS-8Employee plan registration
ARTVArtiva Biotherapeutics8-KCurrent report: results of operations · EX-99.1
ARTVArtiva Biotherapeutics10-KAnnual report
ANTXAN2 Therapeutics8-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1
ADCTADC TherapeuticsS-3Shelf registration
ADCTADC TherapeuticsARSAnnual report to shareholders
ADCTADC Therapeutics8-KCurrent report: results of operations · EX-99.1
ADCTADC Therapeutics10-KAnnual report
ACRSAclaris Therapeutics8-KCurrent report: Reg FD disclosure

Monday, March 932

XNCRXencor8-KCurrent report: agreement terminated
XENEXenon Pharmaceuticals8-KCurrent report: Reg FD disclosure · EX-99.1
XENEXenon Pharmaceuticals424B5Prospectus supplement (offering)
VYGRVoyager Therapeutics8-KCurrent report: results of operations · EX-99.1
VYGRVoyager Therapeutics10-KAnnual report
VERAVera Therapeutics8-KCurrent report: officer / director change
TENXTenax TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
TECXTectonic TherapeuticS-8 POSEmployee plan registration (post-effective)
SPRBSpruce BiosciencesS-8Employee plan registration
SPRBSpruce Biosciences8-KCurrent report: material agreement, agreement terminated, results of operations · EX-99.1
SPRBSpruce Biosciences424B5Prospectus supplement (offering)
SPRBSpruce Biosciences10-KAnnual report
SEPNSepternaS-8Employee plan registration
SEPNSepterna8-KCurrent report: results of operations · EX-99.1
SEPNSepterna10-KAnnual report
SABSSAB Biotherapeutics10-KAnnual report
RNACCartesian Therapeutics8-KCurrent report: results of operations · EX-99.1
RNACCartesian Therapeutics10-KAnnual report
RLMDRelmada Therapeutics8-KCurrent report: material agreement, unregistered sale of equity, Reg FD disclosure · EX-99.1 PRESS RELEASE, DATED MARCH 9, 2026, ANNOUNCING NDV-01 12-MONTH PHASE 2 DATA
NBPNovaBridge Biosciences6-KForeign issuer report · EX-99.1
MLYSMineralys Therapeutics8-KCurrent report: Reg FD disclosure, other events · EX-99.1
MBRXMoleculin BiotechDEF 14AProxy statement
LRMRLarimar Therapeutics8-KCurrent report: other events · EX-99.1
LGVNLongeveron8-KCurrent report: listing notice, officer / director change
KROSKeros Therapeutics8-KCurrent report: other events · EX-99.1
IONSIonis Pharmaceuticals8-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
DRTSAlpha Tau MedicalS-8Employee plan registration
DRTSAlpha Tau Medical6-KForeign issuer report · EX-99.1 PRESS RELEASE DATED MARCH 9, 2026
DRTSAlpha Tau Medical20-FAnnual report (foreign)
CYDYCytoDyn424B3Prospectus (resale / update)
CHRSCoherus Oncology8-KCurrent report: results of operations · EX-99.1
CHRSCoherus Oncology10-KAnnual report
BCTXBriaCell Therapeutics8-KCurrent report: shareholder vote
ATHEAlterity Therapeutics6-KForeign issuer report · EX-99.1 ATH - ALTERITY TO PARTICIPATE IN THE BELL POTTER HEALTH SUMMIT
ATAIAtai BeckleyS-3ASRAutomatic shelf registration
ATAIAtai Beckley8-KCurrent report: material agreement
ANIXAnixa Biosciences10-QQuarterly report

Friday, March 619

Thursday, March 542

ZURAZura Bio8-KCurrent report: Reg FD disclosure · EX-99.1 EXHIBIT 99.1
VERAVera TherapeuticsSCHEDULE 13D/A13D amendment
TNGXTango TherapeuticsS-8Employee plan registration
TNGXTango Therapeutics8-KCurrent report: results of operations · EX-99.1
TNGXTango Therapeutics10-KAnnual report
RVPHReviva Pharmaceuticals8-KCurrent report: holder rights modified, charter / bylaws / fiscal year, other events
PHIOPhio Pharmaceuticals8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
PHIOPhio Pharmaceuticals10-KAnnual report
OTLKOutlook Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
LQDALiquidiaS-8Employee plan registration
LQDALiquidiaS-8Employee plan registration
LQDALiquidiaS-3ASRAutomatic shelf registration
LQDALiquidia8-KCurrent report: results of operations · EX-99.1 EXHIBIT 99.1
LQDALiquidia10-KAnnual report
LCTXLineage Cell Therapeutics8-KCurrent report: results of operations · EX-99.1
LCTXLineage Cell Therapeutics10-KAnnual report
KURAKura Oncology8-KCurrent report: results of operations · EX-99.1
KURAKura Oncology10-KAnnual report
JBIOJade BiosciencesSCHEDULE 13D/A13D amendment
IVVDInvivyd8-KCurrent report: results of operations, other events · EX-99.1
IVVDInvivyd10-KAnnual report
IMTXImmatics6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
IMTXImmatics20-FAnnual report (foreign)
HELPHelus Pharma6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
HELPHelus Pharma6-KForeign issuer report
GHRSGH ResearchS-8Employee plan registration
GHRSGH Research6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
GHRSGH Research20-FAnnual report (foreign)
EYPTEyePoint10-KAnnual report
EVMNEvommuneS-8Employee plan registration
EVMNEvommune8-KCurrent report: results of operations · EX-99.1
EVMNEvommune10-KAnnual report
CYDYCytoDyn8-KCurrent report: unregistered sale of equity
CTNMContineum TherapeuticsS-8Employee plan registration
CTNMContineum Therapeutics8-KCurrent report: results of operations, other events · EX-99.1
CTNMContineum Therapeutics424B5Prospectus supplement (offering)
CTNMContineum Therapeutics10-KAnnual report
CRBUCaribou BiosciencesS-8Employee plan registration
CRBUCaribou Biosciences8-KCurrent report: results of operations · EX-99.1
CRBUCaribou Biosciences10-KAnnual report
CMPXCompass Therapeutics8-KCurrent report: results of operations · EX-99.1 PRESS RELEASE
CMPXCompass Therapeutics10-KAnnual report
CLYMClimb BioS-8Employee plan registration
CLYMClimb Bio8-KCurrent report: results of operations · EX-99.1
CLYMClimb Bio10-KAnnual report
BEAMBeam Therapeutics8-KCurrent report: agreement terminated
BBOTBridgeBio Oncology Therapeutics8-KCurrent report: results of operations · EX-99.1
BBOTBridgeBio Oncology Therapeutics10-KAnnual report
ALTAltimmune8-KCurrent report: results of operations · EX-99.1
AGMBAgomab Therapeutics6-KForeign issuer report

Wednesday, March 427

Tuesday, March 317

Monday, March 247

ZYMEZymeworksS-8Employee plan registration
ZYMEZymeworks8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
ZYMEZymeworks8-KCurrent report: material agreement, debt / obligation, Reg FD disclosure · EX-99.1
ZYMEZymeworks10-KAnnual report
ZURAZura BioSCHEDULE 13D/A13D amendment
XERSXeris BiopharmaS-8Employee plan registration
XERSXeris Biopharma8-KCurrent report: results of operations · EX-99.1
XERSXeris Biopharma10-KAnnual report
VIRVir Biotechnology8-KCurrent report: other events
TYRATyra Biosciences8-KCurrent report: results of operations · EX-99.1
TYRATyra Biosciences10-KAnnual report
TARAProtara TherapeuticsSCHEDULE 13GPassive >5% holder (13G)
SRPTSarepta Therapeutics10-KAnnual report
SIONSionna TherapeuticsS-8Employee plan registration
SIONSionna TherapeuticsS-3ASRAutomatic shelf registration
SIONSionna Therapeutics8-KCurrent report: results of operations · EX-99.1
SIONSionna Therapeutics10-KAnnual report
SEPNSepterna8-KCurrent report: Reg FD disclosure, other events · EX-99.1
RYTMRhythm Pharmaceuticals8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
RNTXRein Therapeutics8-KCurrent report: material agreement, debt / obligation, unregistered sale of equity
RCKTRocket PharmaceuticalsS-3Shelf registration
QUREuniQure8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
QUREuniQure10-KAnnual report
ONCYOncolytics Biotech8-KCurrent report: other events · EX-99.1
NTLAIntellia Therapeutics8-KCurrent report: material agreement, Reg FD disclosure, other events · EX-99.1
NTLAIntellia Therapeutics424B5Prospectus supplement (offering)
NAMSNewAmsterdam Pharma8-KCurrent report: Reg FD disclosure · EX-99.1
MAIAMAIA Biotechnology424B5Prospectus supplement (offering)
LRMRLarimar TherapeuticsSCHEDULE 13D/A13D amendment
KAPAKairos Pharma8-KCurrent report: material agreement, other events · EX-99.1
INABIN8bioSCHEDULE 13GPassive >5% holder (13G)
IMUXImmunicDEF 14AProxy statement
HROWHarrow8-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
HROWHarrow10-KAnnual report
GOSSGossamer BioSCHEDULE 13GPassive >5% holder (13G)
GERNGeronS-3ASRAutomatic shelf registration
GERNGeron10-KAnnual report
EYPTEyePoint8-KCurrent report: other events · EX-99.1
ETONEton Pharmaceuticals8-KCurrent report: material agreement, acquisition / disposition · EX-99.1 EXHIBIT 99.1 PRESS RELEASE RELATING TO HEMANGEOL LICENSING AGREEEMENT
ELTXElicio TherapeuticsS-3/AShelf registration (amended)
DYNDyne TherapeuticsS-8Employee plan registration
DYNDyne Therapeutics8-KCurrent report: results of operations · EX-99.1
DYNDyne Therapeutics10-KAnnual report
DBVTDBV Technologies8-KCurrent report: other events · EX-99.1
CINGCingulateDEF 14AProxy statement
CGTXCognition Therapeutics8-KCurrent report: other events · EX-99.1 EXHIBIT 99.1
CGENCompugen6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
CGENCompugen20-FAnnual report (foreign)
BLTEBelite Bio6-KForeign issuer report · EX-99.1 EXHIBIT 99.1
BCAXBicara TherapeuticsSCHEDULE 13D/A13D amendment
APGEApogee TherapeuticsS-8Employee plan registration
APGEApogee Therapeutics8-KCurrent report · EX-99.1
APGEApogee Therapeutics10-KAnnual report
ADMAAdma Biologics8-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
ACRVAcrivon Therapeutics8-KCurrent report: agreement terminated